Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17357 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Ferenc Török and 5 co-authors. Institution: Department of Pharmacology and Toxicology, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria. Major MEDLINE topics: Calcium Channels, L-Type, Calcium Channel Blockers, Isradipine. Cited 3 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: H2020 Marie Skłodowska-Curie Actions, Austrian Science Fund.
Abstract (original language)
Background and Purpose Pathogenic gain‐of‐function mutations in Ca v 1.3 L‐type voltage‐gated Ca 2+ ‐channels ( CACNA1D ) cause neurodevelopmental disorders with or without endocrine symptoms. We aimed to confirm a pathogenic gain‐of function phenotype of CACNA1D de novo missense mutations A749T and L271H, and investigated the molecular mechanism causing their enhanced sensitivity for the Ca 2+ ‐channel blocker isradipine, a potential therapeutic for affected patients. Experimental Approach Wildtype and mutant channels were expressed in tsA‐201 cells and their gating analysed using whole‐cell and single‐channel patch‐clamp recordings. The voltage‐dependence of isradipine action was quantified using protocols inducing variable fractions of inactivated channels. The molecular basis for altered channel gating in the mutants was investigated using in silico modelling and molecular dynamics simulations. Key Results Both mutations were confirmed pathogenic due to characteristic shifts of voltage‐dependent activation and inactivation towards negative potentials (~20 mV). At negative holding potentials both mutations showed significantly higher isradipine sensitivity compared to wildtype. The affinity for wildtype and mutant channels increased with channel inactivation as predicted by the modulated receptor hypothesis (30‐ to 40‐fold). The IC 50 was indistinguishable for wildtype and mutants when >50% of channels were inactivated. Conclusions and Implications Mutations A749T and L271H induce pathogenic gating changes. Like wildtype, isradipine inhibition is strongly voltage‐dependent. Our data explains their apparent higher drug sensitivity at a given negative voltage by the availability of more inactivated channels due to their more negative inactivation voltage range. Low nanomolar isradipine concentrations will only inhibit Ca v 1.3 channels in neurons during prolonged depolarized states without selectivity for mutant channels.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology and Toxicology, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
- Center of Pharmacology, Institute II, University of Cologne, Cologne, Germany.
- Department of General, Inorganic and Theoretical Chemistry, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
ORCID profiles: Jan Matthes, Jörg Striessnig
Funding
- H2020 Marie Skłodowska-Curie Actions
- Austrian Science Fund
Cite
APA
Török, F., Salamon, S., Ortner, N. J., Fernández-Quintero, M. L., Matthes, J., & Striessnig, J. (2025). Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers. British Journal of Pharmacology. https://doi.org/10.1111/bph.17357
Vancouver
Török F, Salamon S, Ortner NJ, Fernández-Quintero ML, Matthes J, Striessnig J. Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers. British Journal of Pharmacology. 2025. doi:10.1111/bph.17357
BibTeX
@article{Trk2025,
author = {Török, Ferenc and Salamon, Sarah and Ortner, Nadine J and Fernández-Quintero, Monica L and Matthes, Jan and Striessnig, Jörg},
title = {Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17357}
}
EUVIMED